Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$59.23 USD
-0.91 (-1.51%)
Updated May 22, 2024 04:00 PM ET
After-Market: $51.02 -8.21 (-13.86%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
CYTK 59.23 -0.91(-1.51%)
Will CYTK be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CYTK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CYTK
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Tops Revenue Estimates
CYTK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates
Should Vanguard S&P Small-Cap 600 ETF (VIOO) Be on Your Investing Radar?
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Other News for CYTK
Cytokinetics Announces Pricing of Public Offering of Common Stock
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
Cytokinetics Announces Proposed Public Offering of Common Stock
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
Fly Intel: After-Hours Movers